IXICO plc stock analysis
Want to see GB:IXI full AI Analyst Report?
IXICO plc (IXI) Share Price & Analysis
IXI Stock Chart & Stats
- Day’s Range
- GBX 12.50 - GBX 13.50
- 52-Week Range
- GBX 6.26 - GBX 17.00
- Previous Close
- GBX 13.00
- Volume
- N/A
- Average Volume (3M)
- 287.36K
- Market Cap
- GBP 28.47M
- Enterprise Value
- GBP 6.18M
- Total Cash (Recent Filing)
- GBP 1.68M
- Total Debt (Recent Filing)
- GBP 559.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.35
- Next Earnings
- Dec 08, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Order Visibility
Strong H1 growth and an order book covering most of annual guidance provide unusually clear near-term revenue visibility. The 1.75 book-to-bill ratio and rising contracted work support continued commercial momentum, helping management plan delivery and investment with greater confidence.
Improving Gross Margin
The higher gross margin indicates improving economics as IXICO wins more Phase II and III work and increases automated analysis. If this mix and technology contribution persist, operating leverage can strengthen as revenue scales, supporting a more durable path toward eventual profitability.
Strengthened Balance Sheet
The successful raise materially strengthens funding capacity after the pre-raise cash position of GBP 1.7m. Additional liquidity supports planned technology and commercial investment, gives the company more time to develop its platform, and reduces immediate financial pressure while revenue scales.
Bears Say
Persistent Operating Losses
Despite improvement, the business is still loss-making and management does not expect sustainable profitability until 2029. Continued investment in TechBio may prolong earnings pressure, requiring revenue growth and execution to remain strong before the operating model can produce durable profits.
Weak Cash Generation
Negative operating cash flow means reported activity has not yet translated into dependable internal funding. Volatile free cash flow can constrain reinvestment and increase reliance on external capital, particularly while IXICO funds product development and works toward its long-term profitability target.
Delayed TechBio Monetization
The TechBio strategy may improve recurring revenue quality, but product development and regulatory work delay meaningful monetization. This leaves the company dependent on contracted services for the nearer term and increases execution risk around converting the platform roadmap into scalable recurring revenue.
IXICO plc News
IXI FAQ
What was IXICO plc’s price range in the past 12 months?
What is IXICO plc’s market cap?
When is IXICO plc’s upcoming earnings report date?
How were IXICO plc’s earnings last quarter?
Is IXICO plc overvalued?
Does IXICO plc pay dividends?
What is IXICO plc’s EPS estimate?
How many shares outstanding does IXICO plc have?
What happened to IXICO plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of IXICO plc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
IXICO plc
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, from acquisition and processing to in-depth analysis and comprehensive reporting. They leverage proprietary technology platforms like Assessa, a secure digital tool that aids clinical decision-making for patient selection and post-market monitoring, and TrialTracker, which streamlines intricate imaging workflows, handling everything from initial image uploads and quality control to expert analysis, interpretation, and final data delivery within clinical research. IXICO's expertise is concentrated on neurological disorders, including Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and various rare neurological diseases. Their services encompass not only the collection, optimization, and analytics for rare neurological disorders but also drug development analytics, specialized imaging operations, post-market surveillance support, and expert consultancy. The company delivers comprehensive, end-to-end services for clinical trials, covering initial trial design and consultation, meticulous project management, imaging site setup and management, robust data management, expert image reading and analysis, and guidance on regulatory pathways.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bram Goorden
- Employees
- 79
- Website
- ixico.com
- Address
- Griffin Court, London, GL, EC1A 9PN, GB
IXICO plc (IXI) Earnings & Revenues
IXI Earnings Call
Earnings Call SentimentPositive
The call conveyed solid operational progress and strong commercial momentum: double-digit revenue growth (23% in H1), a record GBP 18.1m order book providing 95% coverage of FY26 guidance, improved gross margin (53%), a narrowed EBITDA loss (GBP 0.5m), a successful GBP 10m capital raise and a strategic Medidata partnership that supports productization and scaling. Offsetting these positives are continuing near-term losses, timing risk for TechBio-derived recurring revenue due to productization and regulatory timelines, some exposure to trial descopes/cancellations and the need to convert an increasingly promising pipeline into contracted revenue in large indications like Alzheimer’s and Parkinson’s. Overall, the momentum and balance sheet reinforcement from the capital raise materially outweigh the near-term investment-driven drawbacks, but investors should note the multi-year horizon to realize TechBio recurring revenue and the stated 2029 target for sustained profitability.
View all GB:IXI earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 6 | 4 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 9 | 0 | 3 |











